3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Neoplasm, Residual
1
Interventions
Rituximab
16
zanubrutinib
12
ibrutinib
9
venetoclax
8
Cyclophosphamide
8
pirtobrutinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Sirolimus
5
Mycophenolic Acid
5
Bendamustine Hydrochloride
5
acalabrutinib
4
Peripheral Blood Stem Cell Transplantation
4
Dexamethasone
4
ixazomib
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Cyclosporine
3
Bortezomib
3
Biopsy
3
fludarabine
2
carfilzomib
2
Tacrolimus
2
Prednisone
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
Clonal Evolution
×
1 year
×
Clear all
NCT03521596
2025-11-18
FIL_BIOWM
Fondazione Italiana Linfomi - ETS
Completed
300 enrolled